• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2024.19043

Clinical case of primary multiple metachronous BRCA-associated cancer

[Notes from practice]
Guzel Mustafaevna Salieva; Anatoly Vladimirovich Kubyshkin; Irina Ivanovna Fomochkina; Irina Evgenievna Braude; Anastasia Vladimirovna Kamysheva;

The article offers a clinical case presentation involving the treatment of a patient featuring symptoms of primary multiple metachronous cancer affecting the patient’s breast, and ovaries, associated with the BRCA1c5382insC mutation. From 2007 to 2023, the patient underwent comprehensive treatment, which included surgical, antitumor, and radiotherapy of various modes and targeted therapy with PARP inhibitors. The obtained data reveal the importance of identifying the genetic reason behind tumor growth when dealing with oncological cases.

Download

References:
1. Kaprin A. D., Starinskiy V. V., Shakhzadova A. O. The state of oncological healthcare for the Russian population in 2022. Moscow: P. A. Herzen Moscow Oncology Research Institute, 2013.
2. Baturin V. A., Radzhabov O. V., Baturina M. V., Fil A. A., Grudina E. V. Features of the course of the tumor process in patients with breast cancer, depending on the blood levels of alpha-n-acetylgalactosaminidase and autoantibodies to it. Medical News of North Caucasus. 2023;18(4):386-389. https://doi.org/10.14300/mnnc.2023.18091
3. Shchetinin E. V., Afanaseva G. A., Sirak S. V., Shkodenko O. N., Neredko Yu. S. [et al.] Immunotherapy of tumor diseases. Experimental and Clinical Pharmacology. 2022;85(5):41-48. https://doi.org/10.30906/0869-2092-2022-85-5-41-48
4. Ali A. T. Towards Prevention of Ovarian Cancer. Curr. Cancer Drug Targets. 2018;18(6):522-537. https://doi.org/10.2174/1568009618666180102103008
5. Ledermann J. A. PARP inhibitors in ovarian cancer. Ann. Oncol. 2016;27(1):40-44. https://doi.org/10.1093/annonc/mdw09

Keywords: primary multiple cancer, breast cancer, ovarian cancer, BRCA1, molecular genetic tests, PARP-inhibitors